Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 4/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.44 |
| ▸ | NPY1R | P25929 | 3/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928680 | 0.90 | NPY4R (0.54) | TRPV1SPHK1GAAMAPTCRHBP | |
| SCHEMBL19234501 | 0.87 | SPHK1 (0.53) | SPHK1MAPTCRHBPCRHR2SPHK2 | |
| SCHEMBL22602618 | 0.86 | TRPV1 (0.48) | TRPV1SPHK1GAAMAPTCRHBP | |
| SCHEMBL26445334 | 0.86 | TRPV1 (0.48) | TRPV1SPHK1GAAMAPTCRHBP | |
| SCHEMBL17801791 | 0.86 | SPHK1 (0.51) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL12634418 | 0.86 | SPHK1 (0.51) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL17469339 | 0.84 | LTA4H (0.48) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL25100491 | 0.83 | LTA4H (0.46) | SPHK1SMN1; SMN2SPHK2NPY4RS1PR1 | |
| SCHEMBL20715656 | 0.83 | LTA4H (0.58) | SPHK1GAAMAPTCRHBPCRHR2 | |
| SCHEMBL21849119 | 0.82 | LTA4H (0.47) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | TRPV1 1299/4885SPHK1 405/4885GAA 260/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | TRPV1 1332/4885SPHK1 424/4885GAA 265/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | TRPV1 1299/4885SPHK1 405/4885GAA 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.